Skip to main content
letter
. 2021 Mar 11;13(1):86–88. doi: 10.1136/flgastro-2021-101818

Table 1.

Baseline characteristics of NSBB users and non-users attending a specialist cirrhosis clinic at St Mary’s Hospital, London, UK

Demographics NSBB (n=89) Non-NSBB (n=49) P value
Sex (%) 0.39
 Male 64 (71.9) 31 (63.3)
 Female 25 (28.1) 18 (36.7)
Age (years) (IQR) 58 (49–66) 59 (52–67) 0.47
 Main aetiology (%) 0.52
 Alcohol 48 (53.9) 31 (63.3)
 Hepatitis C 16 (18.0) 7 (14.3)
 Non-alcoholic steatohepatitis 6 (6.7) 6 (12.2)
Disease severity (IQR)
 Child-Pugh Score 8 (8–10) 8 (7–10) 0.39
 Model For End-Stage Liver Disease score 13.50 (11.40–15.80) 11.80 (9.40–14.40) 0.006
Ascites (%)
 None 38 (42.7) 17 (34.7) 0.12
 Mild 24 (27.0) 9 (18.4)
 Moderate 18 (20.2) 11 (22.4)
 Severe 9 (10.1) 12 (24.5)
Hepatic encephalopathy (%) 24 (27.0) 10 (20.4) 0.52
Hepatocellular carcinoma (%) 6 (6.7) 1 (2.0) 0.42
Laboratory parameters (IQR)
 Sodium (mmol/L) 137 (133–139) 137 (135–138) 0.91
 Creatinine (μmol/L) 70 (62–84) 63 (57–73) 0.03
 Albumin (g/L) 29 (25–33) 30 (26–33) 0.33
 Bilirubin (µmol/L) 39 (23–59) 30 (15–52) 0.06
 International normalised ratio 1.3 (1.2–1.5) 1.3 (1.2–1.4) 0.03
 Platelets (×109/L) 96 (66–144) 127 (83–136) 0.03

NSBB, non-selective beta blocker.

HHS Vulnerability Disclosure